Dear Editor

Here, we raise concerns regarding the methodology used and conclusions reached in a recent publication by Saucier et al. \[[@CR1]\] that retrospectively evaluated cases of spontaneously reported opioid overdose in patients treated with extended-release injectable naltrexone (XR-NTX; VIVITROL^®^) using a US FDA dataset. We concentrate on some specific points, but other concerns include failure to cite published data related to longer-term use of XR-NTX \[[@CR2], [@CR3]\], citations of media articles, and the funding of this study by a non-scientific advocacy organization \[[@CR1]\].

Post-marketing safety surveillance is a public health imperative, and Alkermes adheres to rigorous FDA standards regarding the collection, follow-up, and submission of spontaneous case reports for all marketed Alkermes products, including VIVITROL. The most recent Alkermes review of cumulative post-marketing safety data submitted to the FDA (April 2017) evaluated \> 360,000 patients treated with XR-NTX and included the data evaluated by Saucier et al. \[[@CR1]\]. This review did not demonstrate an increased risk of opioid overdose, including fatal overdose, either on treatment with XR-NTX or within 2 months of discontinuation, as implied by Saucier et al. \[[@CR1]\].

Saucier et al. \[[@CR1]\] assert the potential presence of a biologic "rebound effect" following XR-NTX discontinuation (i.e., increased susceptibility to overdose as a result of XR-NTX treatment) \[[@CR1]\]. While animal model data have suggested that chronic naltrexone exposure may lead to an upregulation of opioid receptors in the mouse central nervous system \[[@CR4], [@CR5]\], there is no evidence that the data from animal models translate to an increased risk of overdose as evidenced by human laboratory data \[[@CR6], [@CR7]\] or clinical trial adverse events \[[@CR2], [@CR8]--[@CR13]\]. Lee et al. \[[@CR13]\], who recently reported the results of a National Institute on Drug Abuse (NIDA)-sponsored trial (*n *=570) comparing the effectiveness of XR-NTX and buprenorphine--naloxone (BUP-NX), stated, "So far, no large trial has given a clear signal that XR-NTX treatment increases overdose events or death compared with placebo treatment, treatment as usual, and now BUP-NX treatment." \[[@CR13]\].

We have a number of concerns regarding the methodology used in the analysis. The authors assumed that an "overdose" event was an "opioid overdose" even when the case information regarding the drug(s) taken was missing or unclear \[[@CR1]\]. Applying such adjudication assumptions to missing or incomplete data, which are prevalent in spontaneously reported data, can lead to case misclassification and affect the validity of any conclusions. If such imputation/adjudication methods are used, a sensitivity analysis should be performed in which only cases with clear evidence of stated opioid overdose are used to verify any such conclusion. The authors also took liberties in applying assumptions in their conclusions beyond what was supported by the data. Event latency from the last dose of drug was only known for 28 (54%) of the 52 case reports, yet the authors apply this time course to all 52 events \[[@CR1]\].

There are additional incomplete interpretations of the literature. In describing the comparative effectiveness trial by Lee et al. \[[@CR13]\], Saucier et al. \[[@CR1]\] state that "... a randomized trial had 15 participants who had overdoses (two of which were fatal) in the Vivitrol group (*n *=283 participants; *n *=204 per-protocol group), and eight overdoses (three fatal) in the buprenorphine group (*n *=287; *n *=270 per-protocol group)." It should be noted that some patients within this study had multiple overdoses, and 8 of 18 overdose events in the XR-NTX group were in patients who never received XR-NTX \[[@CR13]\]. The authors further cite an absence of statistical analyses regarding these overdose rates but omit relevant statements from the manuscript \[[@CR1]\]. Lee et al. \[[@CR13]\] state that, while the study was not powered to detect significant differences in overdose, there was no difference in the rate of overdose events between groups and further observed that "most overdose events occurred at times quite distal to the last dose of study medication ... or to discharge from detoxification." Lee et al. \[[@CR13]\] also note, "This outcome makes it difficult to attribute an association between study medication and overdose."

Similarly, Saucier et al. \[[@CR1]\] offer an incomplete interpretation from a study comparing outcomes on methadone, buprenorphine, and a naltrexone implant \[[@CR14]\]. The authors state that the risk of fatal overdose did not differ among groups \[[@CR1]\] but omit the following related result: "rates of non-fatal opioid poisoning were significantly lower in naltrexone-treated patients than in methadone-treated patients following treatment (*p *\<0.001)." \[[@CR14]\].

Saucier et al. \[[@CR1]\] make reference to the XR-NTX registry (NCT01422837) and state that "Alkermes has not yet made the results public." \[[@CR1]\]. In fact, the registry data (*N *=395) have been previously presented at scientific conferences \[[@CR15]--[@CR17]\], and a manuscript has been published \[[@CR3]\]. In this registry, three overdose deaths were reported, which occurred 20 days, 2, and 4 months post-last dose \[[@CR3]\]. It is important to note that these registry case reports were also reported to the FDA and are therefore already included in the dataset analyzed by Saucier et al. \[[@CR1]\]. The authors also incorrectly asserted that Alkermes engages in "the highly unusual marketing practice of mailing starting doses to patients." Alkermes does not mail VIVITROL doses directly to patients; VIVITROL must be prepared and administered by a healthcare provider \[[@CR18]\].

According to the Centers for Disease Control and Prevention (CDC), opioid overdose deaths occurred in 13 per 100,000 people in the USA in 2016, and this rate is increasing \[[@CR19]\]. It is imperative that patients and providers have scientifically accurate information to inform individual treatment decisions. Ongoing efforts to improve access to pharmacological treatments for opioid use disorder and to advance research on the known issue of treatment retention for all FDA-approved medications used in the treatment of opioid use disorder are critical to addressing this epidemic \[[@CR20]--[@CR23]\].
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